" class="no-js "lang="en-US"> Nippon Shinyaku - Medtech Alert
Thursday, March 30, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells
Nippon Shinyaku | Pharmtech Focus

Nippon Shinyaku

About Nippon Shinyaku

Nippon Shinyaku

Related Story

Industry News

 Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku | Pharmtech Focus

Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku

November 10 2021

Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives […]